Literature DB >> 8138909

Adenosine receptor prodrugs: synthesis and biological activity of derivatives of potent, A1-selective agonists.

M C Maillard1, O Nikodijević, K F LaNoue, D Berkich, X D Ji, R Bartus, K A Jacobson.   

Abstract

5'-Ester derivatives of the potent adenosine agonists N6-[4-[[[[4-[[[(2-acetylaminoethyl)amino]carbonyl]methyl] anilino]carbonyl]methyl]phenyl]adenosine (N-AcADAC; 1) and N6-cyclopentyladenosine (CPA; 2) were prepared as prodrugs. Both alkyl esters or carbonates (designed to enter the brain by virtue of increased lipophilicity) and 1,4-dihydro-1-methyl-3-[(pyridinylcarbonyl)oxy]esters designed to concentrate in the brain by virtue of a redox delivery system were synthesized. In the 5'-blocked form, the adenosine agonists displayed highly diminished affinity for rat brain A1-adenosine receptors in binding assays. The dihydropyridine prodrug 29 was active in an assay of locomotor depression in mice, in which adenosine agonists are highly depressant. The behavior depression was not reversible by peripheral administration of a non-central nervous system active adenosine antagonist. In an assay of the peripheral action of adenosine (i.e., the inhibition of lipolysis in rats), the parent compounds were highly potent and the dihydropyridine prodrug was much less potent.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8138909      PMCID: PMC3459066          DOI: 10.1002/jps.2600830112

Source DB:  PubMed          Journal:  J Pharm Sci        ISSN: 0022-3549            Impact factor:   3.534


  22 in total

Review 1.  The cardiac effects of adenosine.

Authors:  L Belardinelli; J Linden; R M Berne
Journal:  Prog Cardiovasc Dis       Date:  1989 Jul-Aug       Impact factor: 8.194

2.  Central versus peripheral mediation of responses to adenosine receptor agonists: evidence against a central mode of action.

Authors:  M S Brodie; K Lee; B B Fredholm; L Ståhle; T V Dunwiddie
Journal:  Brain Res       Date:  1987-07-14       Impact factor: 3.252

3.  AIDS dementia: synthesis and properties of a derivative of 3'-azido-3'-deoxythymidine (AZT) that may become 'locked' in the central nervous system.

Authors:  P F Torrence; J Kinjo; K Lesiak; J Balzarini; E De Clercq
Journal:  FEBS Lett       Date:  1988-07-04       Impact factor: 4.124

4.  N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.

Authors:  A J Bridges; W H Moos; D L Szotek; B K Trivedi; J A Bristol; T G Heffner; R F Bruns; D A Downs
Journal:  J Med Chem       Date:  1987-10       Impact factor: 7.446

5.  Cerebral ischemia in gerbils: postischemic administration of cyclohexyl adenosine and 8-sulfophenyl-theophylline.

Authors:  D K von Lubitz; P J Marangos
Journal:  J Mol Neurosci       Date:  1990       Impact factor: 3.444

6.  Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes.

Authors:  R F Bruns; G H Lu; T A Pugsley
Journal:  Mol Pharmacol       Date:  1986-04       Impact factor: 4.436

7.  A1-adenosine receptor-mediated inhibition of adipocyte adenylate cyclase and lipolysis in Zucker rats.

Authors:  S J Vannucci; C M Klim; L F Martin; K F LaNoue
Journal:  Am J Physiol       Date:  1989-12

8.  Is adenosine an endogenous anticonvulsant?

Authors:  M Dragunow; G V Goddard; R Laverty
Journal:  Epilepsia       Date:  1985 Sep-Oct       Impact factor: 5.864

9.  Improved delivery through biological membranes. 11. A redox chemical drug-delivery system and its use for brain-specific delivery of phenylethylamine.

Authors:  N Bodor; H H Farag
Journal:  J Med Chem       Date:  1983-03       Impact factor: 7.446

10.  Dog coronary artery adenosine receptor: structure of the N6-alkyl subregion.

Authors:  S Kusachi; R D Thompson; W J Bugni; N Yamada; R A Olsson
Journal:  J Med Chem       Date:  1985-11       Impact factor: 7.446

View more
  9 in total

1.  A neoceptor approach to unraveling microscopic interactions between the human A2A adenosine receptor and its agonists.

Authors:  Kenneth A Jacobson; Michihiro Ohno; Heng T Duong; Soo-Kyung Kim; Susanna Tchilibon; Michal Cesnek; Antonín Holý; Zhan-Guo Gao
Journal:  Chem Biol       Date:  2005-02

2.  AMP is an adenosine A1 receptor agonist.

Authors:  Joseph E Rittiner; Ilia Korboukh; Emily A Hull-Ryde; Jian Jin; William P Janzen; Stephen V Frye; Mark J Zylka
Journal:  J Biol Chem       Date:  2012-01-03       Impact factor: 5.157

3.  Synthesis and study of 5'-ester prodrugs of N6-cyclopentyladenosine, a selective A1 receptor agonist.

Authors:  A Dalpiaz; A Scatturin; E Menegatti; F Bortolotti; B Pavan; C Biondi; E Durini; S Manfredini
Journal:  Pharm Res       Date:  2001-04       Impact factor: 4.200

Review 4.  Purinergic system dysfunction in mood disorders: a key target for developing improved therapeutics.

Authors:  Robin Ortiz; Henning Ulrich; Carlos A Zarate; Rodrigo Machado-Vieira
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2014-11-07       Impact factor: 5.067

5.  Structural sweet spot for A1 adenosine receptor activation by truncated (N)-methanocarba nucleosides: receptor docking and potent anticonvulsant activity.

Authors:  Dilip K Tosh; Silvia Paoletta; Francesca Deflorian; Khai Phan; Steven M Moss; Zhan-Guo Gao; Xiaohui Jiang; Kenneth A Jacobson
Journal:  J Med Chem       Date:  2012-09-10       Impact factor: 7.446

6.  Neoceptor concept based on molecular complementarity in GPCRs: a mutant adenosine A(3) receptor with selectively enhanced affinity for amine-modified nucleosides.

Authors:  K A Jacobson; Z G Gao; A Chen; D Barak; S A Kim; K Lee; A Link; P V Rompaey; S van Calenbergh; B T Liang
Journal:  J Med Chem       Date:  2001-11-22       Impact factor: 7.446

7.  Protection against ischemic damage by adenosine amine congener, a potent and selective adenosine A1 receptor agonist.

Authors:  D K Von Lubitz; R C Lin; N Bischofberger; M Beenhakker; M Boyd; R Lipartowska; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1999-03-26       Impact factor: 4.432

8.  Postischemic administration of adenosine amine congener (ADAC): analysis of recovery in gerbils.

Authors:  D K Von Lubitz; R C Lin; I A Paul; M Beenhakker; M Boyd; N Bischofberger; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1996-12-05       Impact factor: 4.432

9.  Reduction of postischemic brain damage and memory deficits following treatment with the selective adenosine A1 receptor agonist.

Authors:  D K Von Lubitz; M Beenhakker; R C Lin; M F Carter; I A Paul; N Bischofberger; K A Jacobson
Journal:  Eur J Pharmacol       Date:  1996-04-29       Impact factor: 4.432

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.